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1. Introduction
There has been a long history of the battle between viral diseases and the mankind. The
arms at our disposal against the virus invasion are continuously expanding its inventory.
Most of them fall into the category of vaccines and antiviral and each of the two kinds of
viral diseases intervention agents has its own advantages and limitations.
2. Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vac‐
cine typically contains an agent that resembles a disease-causing microorganism, and is of‐
ten made from weakened or killed forms of the microbe, its toxins or one of its surface
proteins. The agent stimulates the body's immune system to recognize the agent as foreign,
destroy it, and "remember" it, so that the immune system can more easily recognize and de‐
stroy any of these microorganisms that it later encounters.
Vaccines are dead or inactivated organisms or purified products derived from them.
There are several types of vaccines in use. These represent different strategies used to try to
reduce risk of illness, while retaining the ability to induce a beneficial immune response.
2.1. Inactivated
Some vaccines contain killed, but previously virulent, micro-organisms that have been de‐
stroyed with chemicals, heat, radioactivity or antibiotics. Examples are the influenza vac‐
cine, cholera vaccine,bubonic plague vaccine, polio vaccine, hepatitis A vaccine, and rabies
vaccine.
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2.2. Attenuated
Some vaccines contain live, attenuated microorganisms. Many of these are live viruses that
have been cultivated under conditions that disable their virulent properties, or which use
closely related but less dangerous organisms to produce a broad immune response [1]. They
typically provoke more durable immunological responses and are the preferred type for
healthy adults. Examples include the viral diseases yellow fever, measles, rubella, and
mumps. Attenuated vaccines have some advantages and disadvantages. They have the ca‐
pacity of transient growth so they give prolonged protection, and no booster dose is re‐
quired. But they may get reverted to the virulent form and cause the disease.
Figure 1. H1N1 flu nasal spray as an example of attenuated vaccine
2.3. Subunit
Protein subunit- rather than introducing an inactivated or attenuated micro-organism to an
immune system (which would constitute a "whole-agent" vaccine), a fragment of it can cre‐
ate an immune response. Examples include the subunit vaccine against Hepatitis B virus
that is composed of only the surface proteins of the virus (previously extracted from the
blood stream of chronically infected patients, but now produced by recombination of the vi‐
ral genes into yeast), the virus like particle (VLP) vaccine against human papillomavirus
(HPV) that is composed of the viral major capsidprotein, and the hemagglutinin and neura‐
minidase subunits of the influenza virus. One method of production involves isolation of a
specific protein from a virus and administering this by itself. A weakness of this technique is
that isolated proteins can be denatured and will then bind to different antibodies than the
proteins in the virus. A second method of subunit vaccine is the recombinant vaccine, which
involves putting a protein gene from the targeted virus into another virus. The second virus
will express the protein, but will not present a risk to the injector. This is the type of vaccine
currently in use for hepatitis, and it is experimentally popular, being used to try to develop
new vaccines for difficult to vaccinate viruses such as Ebola and HIV.
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2.4. DNA Vaccine
In the past decade and a half, the DNA vaccine concept has been tested and applied against
various pathogens and tumor antigens [2]. The optimized gene sequence of interest is deliv‐
ered to the skin, subcutaneum or muscle by one of several delivery methods [3]. The expres‐
sion of plasmid-encoded genes will produce foreign antigens and elicits immunological
response. Until now, four DNA vaccine products have been approved, all in the area of vet‐
erinary medicine [4].
Vaccines are very effective on stable viruses, but are of limited use in treating a patient who
has already been infected. It is also difficult to successfully deploy them against rapidly mu‐
tating viruses, such as influenza (the vaccine for which is updated every year) and HIV [5].
Antiviral drugs are particularly useful in these cases.
Vaccine Target Product Name Company involved Date licensedand country
Target
organism Benefits
West Nile virus West NileInnovator
Centers for Disease
Control and Prevention
and Fort Dodge
Laboratories
2005 USA Horses Protects against WestNile virus infection
Infectious
Haematopoietic
necrosis virus
Apex-IHN Novartis 2005 Canada Salmon
Improves animal
welfare, increase food
quality and quantity
Growth hormone
releasing hormone LifeTide-SWS VGX Animal Health 2007 Austrilia
Swine and
food Animals
Increases the number
of piglets weaned in
breeding sows
Melanoma
Canine
Melanoma
Vaccine
Merial, Memorial
Sloan-Kettering Cancer
Center and The Animal
Medical Center of New
York
2007 USA,
conditional
license
Dogs
Treats aggressive forms
of cancer of the mouth,
nail bed, foot pad or
other areas as an
alternative to radiation
and surgery
Table 1. Current licensed DNA therapies (Adapted from Kutzler MA & Weiner et. al)
3. Antiviral agent
Antiviral drugs are a class of medication used specifically for treating viral infections. Like
antibiotics for bacteria, specific antivirals are used for specific viruses. Unlike most antibiot‐
ics, antiviral drugs do not destroy their target pathogen; instead they inhibit their develop‐
ment [6].
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Most of the antiviral drugs now available are designed to help deal with HIV, herpes virus‐
es (best known for causing cold sores and genital herpes, but actually the cause of a wide
range of other diseases, such as chicken pox), the hepatitis B and C viruses, which can cause
liver cancer, and influenza A and B viruses. Researchers are working to extend the range of
antivirals to other families of pathogens.
Designing safe and effective antiviral drugs is difficult, because viruses use the host's cells to
replicate. This makes it difficult to find targets for the drug that would interfere with the vi‐
rus without harming the host organism's cells. Moreover, the major difficulty in developing
vaccines and anti-viral drugs is due to viral variation.
Figure 2. Virus life cycle and targets of antivirals
3.1. Before cell entry
One anti-viral strategy is to interfere with the ability of a virus to infiltrate a target cell. The
virus must go through a sequence of steps to do this, beginning with binding to a specific
"receptor" molecule on the surface of the host cell and ending with the virus "uncoating" in‐
side the cell and releasing its contents. Viruses that have a lipid envelope must also fuse
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their envelope with the target cell, or with a vesicle that transports them into the cell, before
they can uncoat [7].
3.1.1. Entry inhibitor
A very early stage of viral infection is viral entry, when the virus attaches to and enters the
host cell [8]. A number of "entry-inhibiting" or "entry-blocking" drugs are being developed
to fight HIV. HIV most heavily targets the immune system's white blood cells known as
"helper T cells", and identifies these target cells through T-cell surface receptors designated
"CD4" and "CCR5". Attempts to interfere with the binding of HIV with the CD4 receptor
have failed to stop HIV from infecting helper T cells, but research continues on trying to in‐
terfere with the binding of HIV to the CCR5 receptor in hopes that it will be more effective.
3.1.2. Uncoating inhibitor
Inhibitors of uncoating have also been investigated.
Amantadine and rimantadine, have been introduced to combat influenza. These agents act
on penetration/uncoating. They are M2 inhibitors which block the ion channel formed by
the M2 protein that spans the viral membrane. The influenza virus enters its host cell by re‐
ceptor-mediated endocytosis. Thereafter, acidification of the endocytotic vesicles is required
for the dissociation of the M1 protein from the ribonucleoprotein complexes. Only then are
the ribonucleoprotein particles imported into the nucleus via the nuclear pores. The hydro‐
gen ions needed for acidification pass through the M2 channel. Amantadine and rimanta‐
dine block the channel [9].
3.2. During viral synthesis
A second approach is to target the processes that synthesize virus components after a virus
invades a cell.
3.2.1. Reverse transcription
One way of doing this is to develop nucleotide or nucleoside analogues that look like the
building blocks of RNA or DNA, but deactivate the enzymes that synthesize the RNA or
DNA once the analogue is incorporated. This approach is more commonly associated with
the inhibition of reverse transcriptase (RNA to DNA) than with "normal" transcriptase
(DNA to RNA).
An improved knowledge of the action of reverse transcriptase has led to better nucleoside
analogues to treat HIV infections. One of these drugs, lamivudine, has been approved to
treat hepatitis B, which uses reverse transcriptase as part of its replication process. Research‐
ers have gone further and developed inhibitors that do not look like nucleosides, but can
still block reverse transcriptase.
Another target being considered for HIV antivirals include RNase H-which is a component
of reverse transcriptase that splits the synthesized DNA from the original viral RNA.
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Figure 3. Example of the mechanisms of antivirals: Mechanism of action of azidothymidine (AZT). AZT needs to be
phosphorylated, in three steps, to the triphospate form before it can interfere with the reverse transcriptase reaction
3.2.2. Integrase
Another target is integrase, which splices the synthesized DNA into the host cell genome.
There appears to be no functional equivalent of the enzyme in human cells. The biochemical
mechanism of integration of HIV DNA into the host cell genome involves a carefully de‐
fined sequence of DNA tailoring (3'-processing) and coupling (joining or integration) reac‐
tions [10]. In spite of some effort in this area targeted at the discovery of therapeutically
useful inhibitors of this viral enzyme, there are no drugs for HIV/AIDS in clinical use where
the mechanism of action is inhibition of HIV integrase. However there are several promising
candidates in several classes of compounds, including nucleotides, dinucleotides, oligonu‐
cleotides and miscellaneous small molecules such as heterocyclic systems, natural products,
diketo acids and sulfones, that have been discovered as inhibitors of HIV integrase.
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3.2.3. Transcription
Once a virus genome becomes operational in a host cell, it then generates messenger RNA
(mRNA) molecules that direct the synthesis of viral proteins. Production of mRNA is initiat‐
ed by proteins known as transcription factors. Several antivirals are now being designed to
block attachment of transcription factors to viral DNA. Kao et al. recently identified a com‐
pound called nucleozin via random screening, which was found to inhibit influenza by in‐
teracting with influenza NP. Nucleozin causes the NPs to aggregate abnormally, and
consequently inhibits normal viral transcription, crippling the replication cycle by extension
[11]. Examination of a nucleozin analogue revealed that the compound functions by binding
to two copies of NP and forming abnormal dimers, causing the proteins to aggregate and
preventing them from functioning normally. Nucleozin was also shown to inhibit influenza
virus in vitro and in a mouse model, making it a promising candidate for a new antiviral
drug.
3.2.4. Translation/antisense
Genomics has not only helped find targets for many antivirals, it has provided the basis for
an entirely new type of drug, based on "antisense" molecules. These are segments of DNA or
RNA that are designed as complementary molecule to critical sections of viral genomes, and
the binding of these antisense segments to these target sections blocks the operation of those
genomes. A phosphorothioate antisense drug named fomivirsen has been introduced, used
to treat opportunistic eye infections in AIDS patients caused by cytomegalovirus, and other
antisense antivirals are in development.
3.2.5. Translation/ribozymes
Yet another antiviral technique inspired by genomics is a set of drugs based on ribozymes,
which are enzymes that will cut apart viral RNA or DNA at selected sites. In their natural
course, ribozymes are used as part of the viral manufacturing sequence, but these synthetic
ribozymes are designed to cut RNA and DNA at sites that will disable them.
A ribozyme antiviral to deal with hepatitis C has been suggested, and ribozyme antivirals
are being developed to deal with HIV. An interesting variation of this idea is the use of ge‐
netically modified cells that can produce custom-tailored ribozymes. This is part of a broad‐
er effort to create genetically modified cells that can be injected into a host to attack
pathogens by generating specialized proteins that block viral replication at various phases
of the viral life cycle [12].
3.2.6. Protease inhibitors
Some viruses include an enzyme known as a protease that cuts viral protein chains apart so
they can be assembled into their final configuration, such as Saquinavir (Figure 4). HIV in‐
cludes a protease, and so considerable research has been performed to find "protease inhibi‐
tors" to attack HIV at that phase of its life cycle. Protease inhibitors became available in the
1990s and have proven effective, though they can have unusual side effects, for example
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causing fat to build up in unusual places. Improved protease inhibitors are now in develop‐
ment [13].
Figure 4. Protease inhibitor antiviral Saquinavir.
Structure: cis-N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-2-quinolylcarbonyl-
l-asparaginyl]-amino]butyl]-(4aS-8aS)-isoquinoline-3(S)-carboxamide methane sulfonate,
hard gel capsules, Invirase®, also available as soft gelatin capsules (Fortovase®).
Activity spectrum: HIV (types 1 and 2).
Mechanism of action: transition-state, hydroxyethylene-based, peptidomimetic inhibitor of
HIV protease.
3.3. Release phase
The final stage in the life cycle of a virus is the release of completed viruses from the host
cell, and this step has also been targeted by antiviral drug developers. Two drugs named
zanamivir (Relenza) and oseltamivir (Tamiflu) that have been recently introduced to treat
influenza prevent the release of viral particles by blocking a molecule named neuraminidase
that is found on the surface of flu viruses, and also seems to be constant across a wide range
of flu strains [14].
3.4. Considerations in the clinical development of antiviral agents
A total of 37 antiviral compounds (not including interferons or immunoglobulins) have mo‐
mentarily been licensed for the treatment of HIV, HBV, herpesvirus, influenza virus and/or
HCV infections [15]. In the preceding sections these compounds have been discussed from
the following viewpoints: chemical structure, activity spectrum, mechanism of action, prin‐
cipal clinical indication(s). Other points that need to be considered before the full clinical po‐
tential of any given drug could be appreciated, are: (i) duration of treatment, (ii) single-
versus multiple-drug therapy, (iii) pharmacokinetics, (iv) drug interactions, (v) toxic side
effects and (vi) development of resistance. A particular issue that may be important in the
clinical setting is whether the listed anti-HIV agents would be equally suited for the treat‐
ment of HIV-2 and HIV-1 infections.
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As to the duration of treatment, this may vary from a few days (HSV, VZV, influenza virus
infections) to several months or years (HIV, HBV and HCV infections), depending on
whether we are dealing with an acute (primary (i.e. influenza) or recurrent (i.e. HSV, VZV)
infection or chronic, persistent (i.e. HIV, HBV, HCV) infection. For HIV infections it is still
being evaluated whether long-term treatment can be interrupted, without loss of benefit (or
increased benefit) to the patient (structured treatment interruption, STI) [16].
While the short-term treatment (5–7 days) of HSV, VZV and influenza virus infections, and
even the more prolonged treatment of CMV infections, can be based on single-drug therapy,
for the long-term treatment of HIV infections combination of several drugs in a triple-drug
cocktail (also referred to as HAART for ‘highly active anti-retroviral therapy’) has become
the standard procedure, and likewise, the long-term treatment of HBV infections may in the
future also evolve from single- to dual- or triple-drug therapy [17].
Pharmacokinetic parameters to be addressed, when evaluating the therapeutic potential, in‐
clude bioavailability (upon either topical, oral or parenteral administration), plasma protein
binding affinity, distribution through the organism (penetration into the CNS, when this is
needed), metabolism through the liver (i.e. cytochrome P-450 drug-metabolizing enzymes)
and elimination through the kidney. Particularly when concocting the multiple-drug combi‐
nations for the treatment of HIV infection, possible drug–drug interactions should be taken
into account: i.e. some compounds act as P-450 inhibitors and others as P-450 inducers, and
this may greatly influence the plasma drug levels achieved, especially in the case of NNRTIs
and PIs [18].
Toxic side effects, both short and long-term, must be considered when the drugs have to be
administered for a prolonged period, as in the treatment of HIV infections. These side effects
may seriously compromise compliance (adherence to drug intake), and could, at least in
part, be circumvented by a reduction of the pill burden to, ideally, once-daily dosing.
Finally, resistance development may be an important issue, again for those compounds that
have to be taken for a prolonged period, as is generally the case for most of the NRTIs,
NNRTIs and PIs currently used in the treatment of HIV infections. Yet, the nucleoside phos‐
phonate analogues (NtRTIs) tenofovir and adefovir do not readily or rapidly lead to resist‐
ance development, even after more than 1 year of therapy (for HIV and HBV, respectively).
Resistance has been noted with HBV against lamivudine after long-term therapy (>6
months), but, if resistant to lamivudine, HBV infections remain amenable to treatment with
adefovir dipivoxil. As has been occasionally observed in immunosuppressed patients, HSV
may develop resistance to acyclovir, and CMV to ganciclovir, but, if based on ACV TK or
CMV PK deficiency, these resistant viruses remain amenable to treatment with foscarnet
and/or cidofovir [19]. In immunocompetent patients, treated for an acute or episodic HSV,
VZV or influenza virus infection, short-term therapy is unlikely to engender any resistance
problems
The evolution of viral vaccines from the time of Jennerian prophylaxis to today's recombi‐
nant technology has been a continuing story of success. From the relatively crude or "first
generation" vaccines for smallpox, rabies, and yellow fever followed a second and third gen‐
Vaccines and Antiviral Agents
http://dx.doi.org/10.5772/56866
247
eration of improved or new viral vaccines. The application of techniques for attenuating, in‐
activating, and partially purifying candidate viruses yielded safe, effective vaccines against
influenza, poliomyelitis, measles, mumps, and rubella. With the advent of effective national
immunization programs in the United States and other areas of the world to promote wide
scale use of these vaccines, we have seen a dramatic decrease in incidence of the viral infec‐
tions of children. The new biotechnology serves as the cornerstone for a fourth generation of
vaccines and has already provided a licensed recombinant yeast human hepatitis B vaccine.
The prospects for a wide spectrum of new or improved vaccines are highly encouraging, not
only because of the recent technical advances but also because vaccine development has
been recognized as a priority area of research. Under the National Institute of Allergy and
Infectious Diseases' Program for Accelerated Development of New Vaccines, support is be‐
ing provided for developmental vaccine studies with hepatitis A and B, influenza A and B,
rabies, rotavirus, varicella, and respiratory syncytial virus. The outlook for antivirals is
equally optimistic. The same technologies that have provided greater insight into the genet‐
ics and molecular biology of viruses and hence the means to fashion subunit or even syn‐
thetic vaccines have yielded data that can be applied to successful development of targeted
antiviral compounds.
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